XML 167 R84.htm IDEA: XBRL DOCUMENT
v3.20.4

Segmentation of key figures (Details 8) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 48,659 | $ 47,445 | $ 44,751
Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 3.00% | 6.00% |
Innovative Medicines | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | 3.00% | 8.00% |
Operating segments [member] | Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 39,013 | $ 37,714 | 34,892
Net sales, change in % | 3.00% | 8.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 14,711 | $ 14,370 | 13,428
Net sales, change in % | 2.00% | 7.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,958 | $ 1,880 | 1,874
Net sales, change in % | 4.00% | 0.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,738 | $ 1,416 | 1,174
Net sales, change in % | 23.00% | 21.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,542 | $ 1,338 | 1,155
Net sales, change in % | 15.00% | 16.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,439 | $ 1,585 | 1,587
Net sales, change in % | (9.00%) | 0.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,339 | $ 1,114 | 977
Net sales, change in % | 20.00% | 14.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,188 | $ 1,263 | 1,561
Net sales, change in % | (6.00%) | (19.00%) |
Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,083 | $ 1,539 | 1,556
Net sales, change in % | (30.00%) | (1.00%) |
Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 687 | $ 480 | 235
Net sales, change in % | 43.00% | 104.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 653 | $ 975 | 1,099
Net sales, change in % | (33.00%) | (11.00%) |
Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 635 | $ 755 | 828
Net sales, change in % | (16.00%) | (9.00%) |
Operating segments [member] | Innovative Medicines | Oncology [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 474 | $ 278 | 76
Net sales, change in % | 71.00% |  |
Operating segments [member] | Innovative Medicines | Oncology [member] | Lutathera [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 445 | $ 441 | 167
Net sales, change in % | 1.00% | 164.00% |
Operating segments [member] | Innovative Medicines | Oncology [member] | Piqray [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 320 | $ 116 |
Net sales, change in % | 176.00% |  |
Operating segments [member] | Innovative Medicines | Oncology [member] | Adakveo [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 105 | 1 |
Operating segments [member] | Innovative Medicines | Oncology [member] | Tabrecta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 35 |  |
Operating segments [member] | Innovative Medicines | Oncology [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,070 | $ 1,189 | 1,139
Net sales, change in % | (10.00%) | 4.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 24,302 | $ 23,344 | 21,464
Net sales, change in % | 4.00% | 9.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 4,868 | $ 4,222 | 3,392
Net sales, change in % | 15.00% | 24.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 3,995 | $ 3,551 | 2,837
Net sales, change in % | 13.00% | 25.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 873 | $ 671 | 554
Net sales, change in % | 30.00% | 21.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 1
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 4,410 | $ 4,776 | 4,558
Net sales, change in % | (8.00%) | 5.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,933 | $ 2,086 | 2,046
Net sales, change in % | (7.00%) | 2.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Xiidra [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 376 | $ 192 |
Net sales, change in % | 96.00% |  |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Beovu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 190 | 35 |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,911 | $ 2,463 | 1,995
Net sales, change in % | (22.00%) | 23.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 4,323 | $ 3,773 | 3,429
Net sales, change in % | 15.00% | 10.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 3,003 | $ 3,223 | 3,341
Net sales, change in % | (7.00%) | (4.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 920 | $ 361 |
Net sales, change in % | 155.00% |  |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Mayzent [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 170 | 26 |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Aimovig [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 164 | 103 | 8
Net sales, change in % | 59.00% |  |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 15 |  |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 51 | $ 60 | 80
Net sales, change in % | (15.00%) | (25.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 2,498 | $ 1,750 | 1,050
Net sales, change in % | 43.00% | 67.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 2,497 | $ 1,726 | 1,028
Net sales, change in % | 45.00% | 68.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1 | $ 24 | 22
Net sales, change in % | (96.00%) | 9.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,900 | $ 1,825 | 1,767
Net sales, change in % | 4.00% | 3.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,251 | $ 1,173 | 1,039
Net sales, change in % | 7.00% | 13.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Ultibro Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 623 | $ 630 | 703
Net sales, change in % | (1.00%) | (10.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 26 | $ 22 | 25
Net sales, change in % | 18.00% | (12.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 6,303 | $ 6,998 | 7,268
Net sales, change in % | (10.00%) | (4.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,199 | $ 1,297 | 1,284
Net sales, change in % | (8.00%) | 1.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,003 | $ 1,064 | 1,023
Net sales, change in % | (6.00%) | 4.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 980 | $ 1,025 | 1,002
Net sales, change in % | (4.00%) | 2.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 452 | $ 485 | 464
Net sales, change in % | (7.00%) | 5.00% |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 393 | $ 419 | 463
Net sales, change in % | (6.00%) | (10.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 360 | $ 417 | 445
Net sales, change in % | (14.00%) | (6.00%) |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 1,916 | $ 2,291 | $ 2,587
Net sales, change in % | (16.00%) | (11.00%) |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_OphthalmologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_CardioMetabolicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_RespiratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XolairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_EstablishedMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |